Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

The Lancet
Sep 04, 2021 Volume 398 Number 10303 p817-930, e12-e13
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu, et al. with the Com-COV Study Group